Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT

Freigegeben

Zeitschriftenartikel

Plasma-modified dendritic Cu catalyst for CO2 electroreduction

MPG-Autoren
/persons/resource/persons227612

Scholten,  Fabian
Interface Science, Fritz Haber Institute, Max Planck Society;
Department of Physics, Ruhr-University Bochum, 44780 Bochum, Germany;

/persons/resource/persons22020

Roldan Cuenya,  Beatriz
Interface Science, Fritz Haber Institute, Max Planck Society;

Externe Ressourcen
Es sind keine externen Ressourcen hinterlegt
Volltexte (beschränkter Zugriff)
Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.
Volltexte (frei zugänglich)

acscatal.9b00483.pdf
(Verlagsversion), 4MB

Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Scholten, F., Sinev, I., Bernal, M., & Roldan Cuenya, B. (2019). Plasma-modified dendritic Cu catalyst for CO2 electroreduction. ACS Catalysis, 9(6), 5496-5502. doi:10.1021/acscatal.9b00483.


Zitierlink: https://hdl.handle.net/21.11116/0000-0003-9DB3-2
Zusammenfassung
Efficient and active catalysts with high selectivity for hydrocarbons and other valuable chemicals during stable operation are crucial. We have taken advantage of low-pressure oxygen plasmas to modify dendritic Cu catalysts and were able to achieve enhanced selectivity towards C2 and C3 products. Utilizing operando spectroscopic methods such as X-ray absorption fine-structure spectroscopy (XAFS) and quasi in situ X-ray photoelectron spectroscopy (XPS) we observed that the initial presence of oxides in these catalysts before the reaction plays an inferior role in determining their catalytic performance as compared the overall catalysts morphology. This is assigned to the poor stability of the CuxO species in these materials under CO2RR conditions. Our findings shed light into the strong structure/chemical state-selectivity correlation in CO2RR and open venues for the rational design of more effective catalysts through plasma pre-treatments.